BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2021

Sep 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2021-09-01

Reporting Person: Galson Steven K (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-01	Non-Qualified Stock Option	$16.15	A	60000	Acquired	2031-09-01	Common Stock (60000)	Direct

Footnotes

F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan.

F2: The option vests 1/36 per month for a period of 36 months, beginning on October 1, 2021.